On the stock market since 2019, it operates in the world of health and science. It has 1,120 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 258% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 51% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 98% a year on average.
The company sells $1.2B a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $20.00 — 100% above today’s price.
A loss of $11.0M against $1.2B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, TLPPF sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: TLPPF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.